Arend S M, Kroon F P, van't Wout J W
Department of Infectious Diseases, University Hospital, Leiden, The Netherlands.
Arch Intern Med. 1995;155(22):2436-41.
Pneumocystis carinii pneumonia (PCP) occurs in immunocompromised patients without the acquired immunodeficiency syndrome (AIDS). There has been an increasing yearly number of cases of PCP in our patients without AIDS.
To determine the nature of the underlying disorder and previous immunosuppressive treatment in patients with PCP without AIDS.
A study of the charts of 78 such patients admitted to our hospital from 1980 through 1993.
The number of PCP cases per year increased during the period studied. All patients had an underlying disorder, either hematologic malignancy (49%), solid organ tumor (4%), vasculitis or other immunologic disorder (22%), or they had undergone renal transplantation (17%) or bone marrow transplantation (9%). Previous immunosuppressive medication consisted of prednisone or other corticosteroids in 72 (92%) of 78 patients, cytotoxic drugs in 55 (71%) of 78 patients, both in 50 (64%) of 78 patients, and none in one patient. Quantification of previous corticosteroid treatment showed a large variability among patients. The overall mortality rate for patients was 35% (27/78). Mortality was significantly higher in patients with a concomitant pulmonary infection (P = .01), an underlying disorder other than that which resulted in renal transplantation (P = .03), mechanical ventilation (P < .001), previous chemotherapy (P = .04), as well as previous cyclophosphamide treatment (P = .01). A trend toward a higher mortality in patients with previous corticosteroid use was detected (P = .06).
Pneumocystis carinii pneumonia may complicate a variety of immunocompromised states, with considerable mortality. Pneumocystis carinii pneumonia occurred at all levels of immunosuppression; no threshold level could be defined.
卡氏肺孢子虫肺炎(PCP)发生于无获得性免疫缺陷综合征(AIDS)的免疫功能低下患者中。我院无AIDS的患者中PCP病例数逐年增加。
确定无AIDS的PCP患者潜在疾病的性质及既往免疫抑制治疗情况。
对1980年至1993年我院收治的78例此类患者的病历进行研究。
在所研究期间,每年的PCP病例数增加。所有患者均有潜在疾病,包括血液系统恶性肿瘤(49%)、实体器官肿瘤(4%)、血管炎或其他免疫性疾病(22%),或接受过肾移植(17%)或骨髓移植(9%)。既往免疫抑制药物治疗情况为,78例患者中有72例(92%)使用过泼尼松或其他皮质类固醇,78例患者中有55例(71%)使用过细胞毒性药物,78例患者中有50例(64%)两种药物都使用过,1例患者未使用过任何免疫抑制药物。既往皮质类固醇治疗的量化显示患者之间差异很大。患者的总死亡率为35%(27/78)。合并肺部感染的患者死亡率显著更高(P = 0.01),有导致肾移植以外的潜在疾病的患者死亡率显著更高(P = 0.03),接受机械通气的患者死亡率显著更高(P < 0.001),既往接受过化疗的患者死亡率显著更高(P = 0.04),以及既往接受过环磷酰胺治疗的患者死亡率显著更高(P = 0.01)。检测到既往使用皮质类固醇的患者有死亡率更高的趋势(P = 0.06)。
卡氏肺孢子虫肺炎可能使多种免疫功能低下状态复杂化,死亡率较高。卡氏肺孢子虫肺炎在所有免疫抑制水平均可发生;无法确定阈值水平。